JP2019112416A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019112416A5 JP2019112416A5 JP2019026073A JP2019026073A JP2019112416A5 JP 2019112416 A5 JP2019112416 A5 JP 2019112416A5 JP 2019026073 A JP2019026073 A JP 2019026073A JP 2019026073 A JP2019026073 A JP 2019026073A JP 2019112416 A5 JP2019112416 A5 JP 2019112416A5
- Authority
- JP
- Japan
- Prior art keywords
- entinostat
- administration
- exemestane
- combination
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 claims 32
- 229950005837 entinostat Drugs 0.000 claims 32
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims 13
- 229960000255 exemestane Drugs 0.000 claims 13
- 235000020937 fasting conditions Nutrition 0.000 claims 6
- 235000013305 food Nutrition 0.000 claims 4
- 235000012054 meals Nutrition 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361819505P | 2013-05-03 | 2013-05-03 | |
| US61/819,505 | 2013-05-03 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016512076A Division JP2016522188A (ja) | 2013-05-03 | 2014-05-02 | 癌の処置方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019112416A JP2019112416A (ja) | 2019-07-11 |
| JP2019112416A5 true JP2019112416A5 (enExample) | 2019-09-19 |
| JP6860949B2 JP6860949B2 (ja) | 2021-04-21 |
Family
ID=51843995
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016512076A Pending JP2016522188A (ja) | 2013-05-03 | 2014-05-02 | 癌の処置方法 |
| JP2019026073A Active JP6860949B2 (ja) | 2013-05-03 | 2019-02-15 | 癌の処置方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016512076A Pending JP2016522188A (ja) | 2013-05-03 | 2014-05-02 | 癌の処置方法 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP2991650A4 (enExample) |
| JP (2) | JP2016522188A (enExample) |
| KR (1) | KR102337598B1 (enExample) |
| CN (1) | CN105492007A (enExample) |
| HK (1) | HK1223547A1 (enExample) |
| WO (1) | WO2014179738A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017028287A2 (en) * | 2015-06-29 | 2018-09-04 | Syndax Pharmaceuticals, Inc. | COMBINATION OF THE HDAC INHIBITOR AND ANTICORPIDE ANTI-PD- L1 FOR CANCER TREATMENT |
| JP2019524748A (ja) * | 2016-07-20 | 2019-09-05 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | がんの治療におけるエリブリン及びヒストンデアセチラーゼ阻害剤の使用 |
| JP7537874B2 (ja) | 2017-05-19 | 2024-08-21 | シンダックス ファーマシューティカルズ， インコーポレイテッド | 併用療法 |
| US12156866B2 (en) | 2018-06-06 | 2024-12-03 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| RU2680603C1 (ru) * | 2018-11-08 | 2019-02-25 | Ильясов Шамиль Сионович | Применение 3-о-сульфамата-16,16-диметил-d-гомоэквиленина для лечения онкологических заболеваний |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006223086A1 (en) * | 2005-03-11 | 2006-09-21 | The Regents Of The University Of Colorado | Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors |
| EP2046299A1 (en) * | 2006-07-11 | 2009-04-15 | Mutual Pharmaceutical Company, Inc. | Controlled-release formulations |
| US20100305167A1 (en) * | 2007-11-19 | 2010-12-02 | Syndax Pharmaceuticals, Inc. | Administration of an Inhibitor of HDAC |
| BRPI0909818A2 (pt) * | 2008-03-07 | 2015-10-06 | Pfizer | métodos, formas de dosagem e conjunto para administrar ziprasidona sem alimentos |
| CA2725390C (en) * | 2008-04-08 | 2014-09-23 | Syndax Pharmaceuticals, Inc. | Use of a hdac inhibitor and a her-2 inhibitor in the treatment of breast cancer |
| JP6195384B2 (ja) * | 2011-09-02 | 2017-09-13 | シンダックス ファーマシューティカルズ，インク． | 乳癌の処置方法 |
-
2014
- 2014-05-02 KR KR1020157033947A patent/KR102337598B1/ko active Active
- 2014-05-02 WO PCT/US2014/036651 patent/WO2014179738A1/en not_active Ceased
- 2014-05-02 EP EP14791444.4A patent/EP2991650A4/en not_active Withdrawn
- 2014-05-02 CN CN201480038420.7A patent/CN105492007A/zh active Pending
- 2014-05-02 HK HK16111783.0A patent/HK1223547A1/zh unknown
- 2014-05-02 JP JP2016512076A patent/JP2016522188A/ja active Pending
-
2019
- 2019-02-15 JP JP2019026073A patent/JP6860949B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019112416A5 (enExample) | ||
| JP2019048843A5 (enExample) | ||
| JP2022121594A5 (enExample) | ||
| RU2022102537A (ru) | Нейроактивные стероиды, их композиции и применения | |
| US20150174080A1 (en) | Nutritional composition for promoting musculoskeletal health in patients with inflammatory bowel disease (ibd) | |
| JP2023107883A5 (enExample) | ||
| JP2020519295A5 (enExample) | ||
| JP2023153863A (ja) | １５－ｈｅｐｅを含む組成物及びその使用方法 | |
| JP2015503593A5 (enExample) | ||
| JP2014525465A5 (enExample) | ||
| JP2013529665A5 (enExample) | ||
| JP2016522188A5 (enExample) | ||
| Mantovani | Randomised phase III clinical trial of 5 different arms of treatment on 332 patients with cancer cachexia. | |
| JP2017536380A (ja) | １５−ｈｅｐｅを含む組成物、およびそれを用いて線維症を処置または防止する方法 | |
| JPWO2020210418A5 (enExample) | ||
| JP2019535830A5 (enExample) | ||
| JP2016539149A5 (enExample) | ||
| CN112823795A (zh) | 一种特发性肺纤维化药物组合及其应用 | |
| Jagmeet et al. | Kanchnar Guggulu and Varunadi Kashaya in Hypothyroidism-A Case Study | |
| RU2016136666A (ru) | Составы на основе прогестерона | |
| Teng et al. | Neuroprotection of maslinic acid, a novel glycogen phosphorylase inhibitor, in type 2 diabetic rats | |
| JP2016514142A5 (enExample) | ||
| Elgamal et al. | Some risk factors of gallstone formation after laparoscopic sleeve gastrectomy and the role of ezetimibe versus ursodeoxycholic acid in its prevention | |
| JP2019504085A5 (enExample) | ||
| RU2773190C2 (ru) | Введение тазимелтеона в условиях натощак |